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Abstract
While great interest in health effects of natural product (NP) including dietary sup-
plements and foods persists, promising preclinical NP research is not consistently 
translating into actionable clinical trial (CT) outcomes. Generally considered the 
gold standard for assessing safety and efficacy, CTs, especially phase III CTs, are 
costly and require rigorous planning to optimize the value of the information ob-
tained. More effective bridging from NP research to CT was the goal of a Septe 
mber,  2018  trans disci plina ry  workshop. Participants emphasized that replicability 
and likelihood of successful translation depend on rigor in experimental design, in-
terpretation, and reporting across the continuum of NP research. Discussions spanned 
good practices for NP characterization and quality control; use and interpretation 
of models (computational through in vivo) with strong clinical predictive validity; 
controls for experimental artefacts, especially for in vitro interrogation of bioactivity 
and mechanisms of action; rigorous assessment and interpretation of prior research; 
transparency in all reporting; and prioritization of research questions. Natural product 
clinical trials prioritized based on rigorous, convergent supporting data and current 
public health needs are most likely to be informative and ultimately affect public 
health. Thoughtful, coordinated implementation of these practices should enhance 
the knowledge gained from future NP research.
K E Y W O R D S
clinical predictive validity, dietary supplements, model systems, rigor and replicability, value of 
information
1 |  INTRODUCTION
1.1 | Background
Research on health effects of natural products (NPs) has 
often stemmed from traditional use, or from evidence that 
higher consumption of plant foods is associated with bet-
ter health outcomes (see 1 and refs. therein). This research 
has resulted in the successful development of many active 
ingredient-based pharmaceuticals from NPs. In contrast to 
a typical drug development pathway, studies based on tra-
ditional uses or epidemiological data rarely begin with a 
precise understanding of the active molecules or their mo-
lecular mechanisms of action. A growing number of recent 
efforts to elucidate the mechanisms of action of tradition-
ally used NPs have reported finding a complex mixture of 
bioactive constituents that act at multiple targets.2-5 Perhaps 
partly as a result of this still incompletely understood com-
plexity, to date many NIH-supported clinical trials (CTs)a  of 
complex NPs (NPCTs), in particular the majority of large, 
randomized, controlled clinical trials (RCTs), have failed to 
reject the “null hypothesis,” that is, they detected no signifi-
cant difference between the intervention and negative con-
trols.6-8 While CTs that fail to reject their null hypothesis can 
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still provide invaluable guidance, the results of such trials 
are often met with concerns that different design choices—
whether of product, dose, timing, participant eligibility cri-
teria, outcomes, etc.—might have yielded a substantially 
different result. Each interventional trial represents a substan-
tial investment, with well-powered Phase III CTs typically 
consuming more than $10 million and many person-years.9,10 
Additionally, as time and funds are limited, and participant 
pools may also be constrained, a decision to invest in a CT 
often precludes pursuing other research questions,11 which 
may provide more useful public health-relevant knowledge 
than an RCT with an insufficient evidence base.
1.1.1 | Definitions
NPs were defined as including materials such as animals, ma-
rine organisms, plants/botanicals/herbals, macroscopic fungi, 
bacteria, probiotics, and minerals, and materials derived from 
them, including isolates, extracts, vitamins, and amino acids. 
NPs may vary in chemical complexity, ranging from crude to 
extensively purified materials, and were considered to include 
dietary supplements, certain foods, traditional medicines, and 
other products derived from multiple natural sources.
Complex NPs: NP preparations which retain a large num-
ber of chemical constituents whose relative concentrations 
and chemistry (metabolome composition) reflect the inher-
ent variability of the sources, as opposed to products consist-
ing of a very limited number of highly purified NP-derived 
constituents.
1.1.2 | Challenges to be addressed
For investigation of traditionally used NP, research design 
may be complicated by the chemical complexity and inher-
ent variability of the NPs.12-14 The often incomplete and/or 
conflicting information on mechanisms of action, appropri-
ate uses, and expected health effects poses challenges for 
formulating hypotheses and designing CT. The ready avail-
ability of a variety of preparations of similar NPs and their 
occurrence in complex matrices such as foods or dietary sup-
plements further increases the challenges for the design, con-
duct, and interpretation of NPCTs.15-17 The variety of NPs 
in the marketplace poses challenges for product selection; in 
addition, participants must be monitored for inadvertent or 
otherwise unreported exposure to the intervention or com-
ponents thereof (drop-ins). Here, consistent with the NIH 
definition, we use the term CT not only for efficacy trials 
but also for any study in humans which assesses NP safety, 
bioavailability, pharmacokinetics (PK), pharmacodynamics 
(PD), dose-response, mechanisms of action, and biological 
markers thereof.
1.2 | Focus and objectives
To discuss good practices for addressing these challenges, 
a two-day, public workshop on September 13 and 14, 2018 
brought together speakers and attendees across disciplines 
and from academia, government, industry, and private prac-
tice at the NIH campus in Bethesda, Maryland. Past efforts 
to enhance rigor in NP research include the NCCIH Policy 
on Natural Product Integrity18 as well as numerous guid-
ance documents addressing identification, reproducibility, 
study design, and execution, as well as conflict of interest 
issues.6,19-27 As was done for a recent workshop focused on 
fatty acids,28 we assemble here relevant prior publications 
citing critical or state-of-the-art approaches drawn from a 
breadth of NP research and related disciplines, and address 
in greater depth NP-related topics that were specific foci of 
the workshop.
Reproducibility, replicability, and other critical charac-
teristics of a solid evidential foundation have been variously 
defined in different sub-disciplines.29,30 Consistent with the 
2019 NASEM Report on Reproducibility and Replicability in 
Science,31 this article uses the term reproducibility for “ob-
taining consistent results using the same input data, computa-
tional steps, methods, and code, and conditions of analysis,” 
and the term replicability for “obtaining consistent results 
across studies aimed at answering the same scientific ques-
tion, each of which has obtained its own data.”
The workshop was predicated on the premise that adherence 
to a well-integrated set of good practices along the continuum 
from ethnobotany and epidemiology through basic biomedical 
research to CTs should enhance the effectiveness of translation 
from preclinical research and early phase CTs to information 
usable by consumers, manufacturers, practitioners, research 
funders, and other stakeholders. The good practices should also 
help reduce premature initiation of Phase III NPCTs, thus reduc-
ing instances producing strong grounds for post-trial concerns 
about the evidence base for a given trial. This article summa-
rizes and updates the workshop discussions of such practices, 
which include those that apply to individual sub-disciplines, 
as well as productive combination of approaches across disci-
plines. The integration of all of these practices, along with the 
application of sound inductive reasoning, rigorous, appropri-
ate, and transparent statistical analyses (Table 1),32-36 as well 
as targeting an effect size that is significant to clinicians and 
consumers37 should increase the replicability and translational 
relevance of basic and preclinical NP research. Ultimately, this 
will serve to limit resources expended on flawed premises pro-
ducing irreplicable data,38-40 and to ensure optimal knowledge 
gained from every NPCT, regardless of whether the results are 
consistent with benefit, harm, or absence of an effect on the 
assessed outcome(s).
This review summarizes areas of both consensus and 
contention that emerged from the workshop discussions. 
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While the workshop focused on approaches to improve 
the knowledge gained from future randomized, controlled, 
NPCTs, some attendees questioned the appropriateness of 
and need for such trials, especially for traditionally used 
botanical preparations, arguing that beneficial effects of 
such practices cannot be detected in the context of a con-
ventional CT.
Moving from a narrower to a broader and more ap-
plied focus, this review begins with good practices for 
the application of assays used to elucidate NP bioactive 
constituents, and continues through the specification and 
characterization of NP interventions, endogenous and 
exogenous factors that may influence the translational rel-
evance of preclinical in vivo models, and the strengths and 
weaknesses of a broad range of state-of-the-art models. 
Subsequently, the review will address additional factors 
that influence the likelihood of successful translation to 
humans, including assessment of the supporting research, 
and concludes with approaches for evidence-based priori-
tization of this research. The review is organized into four 
main sections:
• Good practices for preclinical NP studies
• NP characteristics critical for replicability
• Translational relevance of preclinical NP research
• Good practices for moving to NPCTs
Figure 1 provides the graphical overview of the relationships 
among the covered topics, and Table 1 highlights broadly ap-
plicable good practices. The subsequent tables highlight good 
practices from each of the four main sections:
• Table 2 highlights the good practices for the use of in vitro 
and in silico models.
• Table 3 highlights the good practices for NP selection, for-
mulation, and characterization.
• Table 4 highlights the good practices for the use of preclin-
ical in vivo models.
• Table 5 highlights the critical considerations in NPCT 
design.
• Table 6 highlights the issues to consider in NPCT 
decision-making.
2 |  GOOD PRACTICES FOR 
PRECLINICAL NP STUDIES
2.1 | Optimizing the use of in vitro, 
invertebrate, and in silico models and 
ethnobotanical approaches
Good practices in model systems (in vitro, invertebrate, in 
silico) and in translating from traditional medical systemsb  
to clinical research can enhance the replicability and transla-
tional relevance of preclinical NP studies. To date, the appli-
cation of invertebrate model systems and some newer in vitro 
models has been very limited in NP research.
The measurement of activity in in vitro assays is a typical 
starting point for research on potential clinical application(s) 
of a NP. Good practices in proceeding from other starting 
points are discussed below. In vitro assays are also commonly 
used for monitoring the stability and potency of NPs, as well 
as for identifying fractions or components responsible for the 
T A B L E  1  Highlights of broadly applicable good practices for 
enhanced replicability, transparency, and translational relevance of NP 
research
1. Models, by definition, differ from the actual subject of interest, 
however, when carefully chosen to address a clearly defined ex-
perimental question they can provide critical insights.235 Sound 
inductive reasoning, including careful consideration of differ-
ences between the model and the actual subject of interest, must 
be used in interpreting model system outcomes, for example, 
response in an experimental model may demonstrate a biologi-
cally relevant activity, but does not imply clinical efficacy.
2. Quality control. Ongoing, discipline-appropriate quality control 
is critical for all experimental assays and research components, 
from NP, through cell lines, microphysiological systems,58 in 
silico, and whole-organism models, to CT procedures.
3. Replication is critical: within and across distinct model systems, 
with methods based on orthogonal principles, and in multiple 
labs. Results that replicate across models, methods, labs, are 
more likely to replicate in a CT.
4. Rigor. The same rigorous practices used in CT to avoid bias and 
enhance replicability should be applied in hypothesis-testing 
experiments that may be used in designing a CT. This includes 
randomization of wells/dishes/animals, masking/blinding of 
study personnel, and sample size calculations. Exploratory stud-
ies merit equally complete and transparent reporting but may 
accommodate less stringent procedures.
5. Reporting. Use approaches and venues that support more com-
plete, transparent, and cumulative reporting.
a. Registration: use registered reports and pre-publication regis-
tries for preclinical in vivo studies as well as CT, for example, 
clini caltr ials.gov and precl inica ltria ls.eu. Information needed 
to replicate research on complex NPs may go substantially 
beyond the intervention characterization required by these 
sites, see, for example, nccih.nih.gov/resea rch/polic ies/natur 
alpro duct.htm
b. Outlet: publish in journals that do not limit supplemental 
information.
c. Publish: exploratory studies (without forcing them into 
hypothesis-testing frameworks) and null results of hypothesis-
testing studies.
d. Openness: curate key information for scientific research in 
publicly accessible databases, for example, curat escie nce.org.
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assayed bioactivities. The replicability of these assays depends 
on many inputs, beginning with the test article, which often 
is a chemically complex NP. Good practices to enhance the 
replicability of vertebrate cell culture-based assays have been 
described elsewhere,38,39,41 as have recommendations for the 
use of antibodies.42 The following, therefore, focuses on issues 
more specific to the use of NPs in cell-based assays, and on ap-
proaches to enhance the translational relevance of those assays.
Data generated by high-throughput screens (HTS) and in 
vitro bioactivity assays pose many challenges for interpre-
tation, importantly including their high potential for false 
discovery. Small molecule NP constituents and their spon-
taneous breakdown products and/or metabolites43,44 have 
significant potential to generate in vitro assay artefacts via ag-
gregation,45 fluorescence, light absorption, metal chelation, 
plasma or intracellular membrane disruption,46,47 protein de-
naturation, and/or specific and non-specific reactivity with bi-
ological nucleophiles (Table 2). For example, HTS and other 
in vitro studies of extracts and other preparations derived 
from Curcuma longa (turmeric; often improperly designated 
as “curcumin”) are susceptible to confounding due to the low 
stability44 and high reactivity of the curcuminoids, as well as 
the frequent lack of clarity as to the actual composition of 
a given preparation.48,49 Workshop speakers emphasized the 
need to design and conduct in vitro experiments in ways that 
mitigate and/or reveal such artefacts,41,50,51 for example, by 
time course and chemical analyses, as well as by comprehen-
sive and transparent reporting of experimental parameters.
2.2 | In vitro models
In vitro approaches leverage simplified models of more 
complex biological systems in the interests of higher 
throughput and increased ability to decipher causal mech-
anisms (Table 1). In vitro models that better reflect the 
biology of an intact organism have been developed, tak-
ing advantage of advances including the use of primary, 
patient-derived cells and stem cells, direct differentiation 
of induced pluripotent stem cells, more precise methods of 
gene replacement, and identification and quantification 
of heterogeneity in vivo and in vitro. In vitro models are 
F I G U R E  1  Critical information for the design, implementation, and interpretation of natural product clinical trials. Elucidating details 
(light bulbs) of molecular mechanisms of action prior to initiating a NPCT can help “de-risk” the planned trial by both providing evidence for 
the hypothesized outcome and its underlying causes, and supporting the development of methods to test that hypothesis. It is a good practice for 
researchers to establish standard procedures for product preparation (A), that are optimized for bioactivities and stability, and methods, preferably 
validated, for thorough characterization of product chemistry and stability. Elucidation of the bioactive NP constituents or metabolites (B) is 
critical for quality control, for assessing bioavailability, PK and PD, and determining whether minimal effective concentrations of bioactives have 
been achieved in plasma or at the targets (C). These data can support the development of methods to test mechanistic hypotheses, for example, by 
measuring in vivo engagement of the putative targets, proximate bioactivities, or PD, and/or assessing the relationships between these and (D) the 
primary and secondary NPCT outcomes, and any adverse events 
46 |   SORKIN et al.
also increasingly leveraging advances in tissue engineer-
ing, microfluidics, and real-time biosensors of physiologi-
cal processes. These in vitro models range in the extent to 
which they mimic in vivo conditions from relatively simple 
spheroids,52 through patient tissue-derived organoids, self-
organizing stem-cell-based organoids,52,53 single “organs 
on chips” (OoC) under flow, and integrated, multi-OoC 
microphysiology systems (MPS).54-60 While still relatively 
high-throughput, these models from both healthy and 
diseased tissues have greater similarity to the chemistry, 
three-dimensional structure and component localization, 
environment, and possibly genetic stability of an intact or-
ganism than classical cell cultures grown on relatively flat 
substrates. Moreover, through the use of human-derived 
cells, these models may partially address the challenge of 
species differences in responses (Table 2).61-64 MPS also 
allow targeted assessment of cell-type- or organ-specific 
dose responses (Table 4). Some major challenges in the 
use of MPS and other complex in vitro systems have re-
cently been addressed, including the development and im-
plementation of metrics for replicability and approaches to 
prevent the artefactual binding of hydrophobic molecules 
to the devices.59,65 Models incorporating elements of the 
human immune system are beginning to be developed.66 
However, understanding how to translate results from in 
vitro systems such as MPS to CT, for example, into calcu-
lated dose ranges remains challenging.
Only those effects observed in vitro at concentrations 
achievable in vivo following ingestion, or in systems that 
incorporate upstream components modeling the functions of 
the gastrointestinal tract,67 are likely to be clinically relevant 
to oral dosing. Activities observed only at higher concentra-
tions than can be obtained following ingestion should not be 
over-interpreted in planning CTs of ingested products (Table 
2). Notably, many NP constituents show very limited oral 
bioavailability. Ex vivo models may be used for extensive 
pharmacodynamic characterization of NP, but they do not 
fully recapitulate human physiology. For instance, a prom-
ising NP candidate in an in vitro cell screening assay may 
be metabolized by the liver into an ineffective or even toxic 
byproduct.68 In vivo validation of in vitro results remains a 
key component of preclinical studies.
Speakers described several approaches to manage the 
sometimes limited or conflicting information on NP biolog-
ical activities and their underlying mechanisms, including de-
termining which NP components and cellular and molecular 
targets are required for activity in animals. The application to 
chemically complex NPs of agnostic (or non-targeted) in vitro 
assays69 combining cutting-edge computational approaches, 
optimized mass spectrometric (MS) data collection and 
analysis to elucidate chemical composition, and cytological 
profiling70,71 now enables the generation of strong and spe-
cific hypotheses regarding bioactive NP components and the 
mechanisms through which they affect gene expression or cell 
phenotype.72-76 Such systems have the ability to interrogate 
multiple chemical components and their combinations simul-
taneously, without purification of individual constituents. This 
ability is critical, given accumulating evidence (consistent 
with tradition) that multiple chemical constituents in even a 
single botanical extract may contribute to bioactivity via dis-
tinct or similar molecular mechanisms.77,78 These may include 
effects by constituents on each others’ solubility (or other as-
pects of bioavailability) or toxicity.5,79 These novel, non-tar-
geted platforms also have the advantage of generating strong, 
testable mechanism of action hypotheses without requiring 
assumptions or prior knowledge regarding those mechanisms.
2.3 | Invertebrate in vivo models
Invertebrate models such as Caenorhabditis elegans80,81 and 
Drosophila melanogaster are popular in a variety of research 
areas for their ability to provide relatively high-throughput, 
but in vivo platforms. The conservation of many human genes 
and signaling networks, combined with the small size and 
relatively short lifespans of these models, facilitates the cost-
effective evaluation of a variety of phenotypes (eg, reproduc-
tion, locomotion, cognition) in a large number of individuals 
(Table 4).80 This provides the ability to study phenotypes that 
are challenging to assess in most vertebrate animal models, 
such as healthspan (the part of an organism’s lifespan dur-
ing which it is healthy).82,83 Invertebrate models can also be 
T A B L E  2  Highlights of good practices for the translational 
relevance of in vitro models assessing NP bioactivities and 
mechanisms of action
1. Artefacts. When using in vitro assays of NP activity, test for 
common types of NP assay interference, for example, fluores-
cence or absorption, membrane disruption, protein denaturation, 
and specific and non-specific reactivity with nucleophiles.48
2. Bioavailability. If in vitro activity is observed only at concentra-
tions substantially higher than those achievable in vivo in the 
tissue of interest, then the probability of seeing a robust clinical 
effect of consuming the NP is likely insufficient to form the 
basis for a NPCT.
3. Non-specific molecular mechanism(s) of action. Include controls 
for non-classical mechanisms of action such as metal chelation,87 
modulation of DNA modifying enzymes, or intercalation into 
plasma or subcellular membranes.46,87
4. Biomimetic in vitro models. Consider pros and cons of more 
morphologically detailed “3D” models using human-derived 
cells. Organoids, “organs-on-a-chip” (OoC), and multi-organ 
biomimetic models (eg, human-derived intestine, liver, and 
kidney OoC coupled by appropriate microfluidics) can yield 
more translationally relevant high-throughput information than 
monolayer cell cultures, and are a powerful complement to 
preclinical in vivo models.
   | 47SORKIN et al.
used in more focused interventional and mechanistic studies 
that explore specific aspects of an established phenotype.84-86 
For example, tea polyphenols were reported to modulate both 
stress responses and fertility in D. melanogaster strains87 via 
a non-target-ligand mechanism of action (Table 2), by mod-
ulating iron homeostasis. Recent advances in omics tech-
nology and the use of outbred populations further expand 
opportunities for using D. melanogaster as a model system 
for NP preclinical studies.
2.4 | In silico models
When information on NP kinetics, dynamics, bioavailability, 
clearance, and pharmacologic activities is limited, one use-
ful approach is to apply computational or in silico methods 
to leverage information from products with known chemis-
try, mechanisms of action, and activities. Data from more 
highly characterized products can be integrated into dynamic 
models, and in vitro to in vivo extrapolation (IVIVE) can be 
used to predict biological responses.88-92 These approaches, 
as outlined by the Tox21 Federal collaboration and the U.S. 
Environmental Protection Agency’s ToxCast program,93-96 
can be used to focus high-throughput in vitro and in vivo test-
ing on compounds and concentrations that are more likely 
to be biologically active and appropriate for each model.97,98 
Such integrated approaches could be further developed to 
probabilistically model the pharmacological and toxicologi-
cal kinetics and dynamics of complex NPs.99
Speakers described several critical, often broadly appli-
cable considerations for utilizing in silico models. First, the 
purpose of the model must be clearly defined, and the model 
appropriate and sufficient to fulfill the purpose. Second, as 
for any research, if experiments that provide the input data 
are not appropriately designed in the beginning, no amount 
of computational modeling will yield translatable informa-
tion. Third, variability and uncertainty in the data that in-
form the model, as well as correlations between parameters 
must be considered. Uncertainty and variability in model 
outcomes are acceptable but must be quantified, and in opti-
mized models they should be similar to real-world variabil-
ity. Preliminary models may be continuously refined, using a 
“learn and confirm” strategy, or as understanding, for exam-
ple, of NP pharmacology increases. Fourth, end users must 
understand the computational (or any other) model’s limita-
tions, the extent to which it is similar or dissimilar to the bio-
logical system of interest, and how the outputs compare with 
population-derived data, other real-world data, or with data 
from other models. Finally, computational models and the 
data used in their development must be made findable, freely 
accessible, interoperable and reusable (FAIR),100 just as in-
formation for in vitro and preclinical in vivo models must be 
findable and sufficiently transparent to support replication.
2.5 | Ethnobotanical approaches
Another typical starting point for translational research is 
traditional NP use, particularly the use of plants in traditional 
medical systems. When basing NP research on traditional 
use, it is essential to consider and thoroughly document how 
the NP is sourced, identified, prepared, and used in the tradi-
tional contexts (Table 3). Intra-species variation and grow-
ing conditions strongly influence the metabolic profile of 
a plant and differences in harvest and preparation will also 
alter critical product characteristics.101,102 Many different 
uses may be described for a given species, and traditional 
healers have frequently been reported to use only specific 
subtypes of a given species. Awareness of such practices 
has the potential to be highly informative for the identifica-
tion of bioactive components.103 Analogous considerations 
apply to fungal and animal sources of NP. Good practices 
for reporting botanical NP sourcing, identification, charac-
terization, vouchering and archiving have been previously 
described elsewhere.12,18,19,104-106 Comprehensiveness and 
transparency in reports of biomedical research on tradition-
ally used plants have increased in recent years.107 There 
T A B L E  3  Highlights of good practices for NP integrity including 
standardization, formulation, characterization, and quality control
1. Quality control. Identity and purity of all materials used, 
regardless of the supplier, should be verified (independent of 
supplier) prior to use. Appropriate storage and handling condi-
tions should be maintained and monitored by stability testing 
at least throughout the duration of the study (consult, eg, the 
NCCIH Natural Product Integrity Policy18 and the NSF Stability 
Testing Guidelines for Dietary Supplements). To the extent 
feasible, comprehensive chemical analysis of product should 
be performed; minor product components or impurities can be 
responsible for or affect measured activities.
2. Product specifications:
a. Chemistry. Identification of product components required 
for the bioactivities studied provides critical information for 
studies of bioavailability, pharmacokinetics (PK), and phar-
macodynamics (PD) and should enhance the replicability and 
clinical relevance.
b. Formulation. Consider the effects of NP formulation and ma-
trix (eg, capsule, liquid, food) on bio-accessibility, bioavail-
ability, PK, PD, and activity. These may differ significantly 
between an isolated NP constituent and the same compound in 
the context of a complex food matrix.
c. Sensory characteristics. Sensory acceptability must be consid-
ered for all in vivo research, and effectiveness of masking of 
placebos or active comparators must be considered in CT.
3. Translation from ethnomedicine. If basing an intervention on 
ethnobotanical observations, consider replicating traditional 
practice as closely as is feasible. For example, highly processed 
extracts will likely have different activities than a multi-botani-
cal decoction (see 2a and 2b). Contextual differences (environ-
ment, behavior, genetics) may also affect the outcomes.
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are cases, however, where the available records predate the 
availability of geolocation data on growing sites, or where 
the need to protect ecologically or culturally sensitive in-
formation may limit what can be published.108,109 Where a 
similar use or outcome is reported for the same or closely 
related species across cultures and geographical regions, 
those similarities may provide priority clues for transla-
tional research.
Translation from traditional to modern practice may be 
limited by important differences110 (Table 3). Traditional prac-
tices commonly combine multiple NP sources (eg, multi-bo-
tanical) into one intervention and are often associated with 
specific concurrent behaviors (eg, rituals, behavior changes, 
possibly including dietary changes). Moreover, if documented 
traditional practices and the NP outcomes to be studied differ 
substantially, it may be inappropriate to claim the traditional 
or typical use as supporting data; the differences between 
modern medical diagnoses and practices and traditional prin-
ciples of diagnosis and practice may be too divergent to base 
claims for modern application on traditional use. Moreover, 
where a planned NPCT is expected to use a highly processed 
(single) botanical, information from traditional use may also 
lack relevance, as the bioactivity and/or the absorption, distri-
bution, metabolism, and excretion (ADME) properties of the 
highly processed product may differ substantially from those 
of a (multi-component) traditional preparation. Where the NP 
and the study population are close to historical use and users, 
traditional practice may provide initial parameters for dose 
range to be used in research. In instances where no clear typ-
ical usage exists, for example with green tea extract capsules, 
speakers recommended that preclinical studies prioritize the 
determination of a therapeutic window and administer the 
lowest dose to achieve concentrations required for the biolog-
ical and/or health effect of interest.9
3 |  NP CHARACTERISTICS 
CRITICAL FOR REPLICABILITY
3.1 | NP specifications and integrity
The ultimate biological effect of an ingested, complex NP 
results from a dynamic interplay of factors: NP chemical 
composition, physical characteristics,111,112 bioaccessibility, 
bioavailability, metabolism, and target population charac-
teristics including sex, age, genetics, background diet, and 
other environmental exposures.113 This subsection begins by 
summarizing issues inherent to the integrity of the NP inter-
vention and subsequently addresses target-related sources of 
variability.
Replicability of outcomes depends on correct and 
clearly reported identification and archiving of source 
materials12-14,17 and consistent preparation and activity of 
the NP.17,22,26,114 Some attendees felt that since the effects 
of complex NP preparations may not be due to only the 
identifiable components, transparent reporting of methods, 
including consistent product preparation and quality con-
trol via an in vitro assay relevant to bioactivity, is sufficient 
for replicable NP research. Others argued that in many re-
search context it is also critical to understand which NP 
components are responsible for the bioactivities of inter-
est, as this information can inform NP quality control, as 
well as being utilized in assessments of bioavailability, 
pharmacokinetics and to inform comparisons of different 
studies115 (Table 4).
Minor product components, impurities, instability, and 
chemical changes due to instability, resulting in the oc-
currence of degradation products can be responsible for 
some or even all measured activity. Instability has been 
demonstrated for a variety of prominent bioactive botanical 
marker compounds. These include ligustilide (a constituent 
of dong quai), which is very unstable and prone to redox re-
actions and photo-induced dimerization;43,116,117 desmeth-
ylxanthohumol, a chalcone found in Humulus lupulus, or 
hops, that forms the phytoestrogen, 8-prenylnaringenin, 
via Michael addition;118 and curcumin, found in turmeric, 
which is known to form a myriad of degradation products 
and metabolites.44 These chemical changes can modify bio-
activity through a variety of mechanisms97,119,120 and repre-
sent factors that appear to be minor (Residual Complexity, 
see go.uic.edu/resid ualco mplexity), but may significantly 
alter biological activities and therefore require monitoring. 
A number of organizations have published general guide-
lines for stability testing, which are relevant for dietary 
supplements and other NPs, including the NCCIH Policy 
on Natural Product Integrity18 and guidelines published 
by the International Council for Harmonisation (ICH; ich.
org).
Variations in growing conditions generate variations in 
relative levels of NP constituents; differences in constit-
uent levels are also seen between closely related species 
interchangeably used in similar contexts NP.121 For exam-
ple, the licorice source plants, Glycyrrhiza glabra L. and 
G. uralensis Fisch. ex DC differ significantly in the ratio 
of liquiritigenin to isoliquiritigenin, as well as in conge-
neric constituents, and are therefore expected to have dif-
ferent bioactivities.122,123 Characterization sufficient for the 
detection of such minor components, known or unknown, 
is therefore critical for quality control and for monitoring 
batch-to-batch variation and stability.15,124 Identity and pu-
rity of all materials used, regardless of the supplier, should 
be verified prior to use.14,124 Descriptions of approaches 
to NP selection and characterization have been published 
recently.17,22,114,125
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3.2 | Chemical and metabolic factors
ADME is a multistep, dynamic biological process that may 
be modified by product characteristics as well as by host 
characteristics115,126-129 including physiology and behavior. 
NP processing methods and final formulation can alter the 
chemical profile, stability, bioaccessibility, bioavailability, 
and metabolism of a NP.111,130 For example, soy germ isofla-
vone glucosides incorporated into pasta can be hydrolyzed to 
aglycones by wheat β-glucosidase.131
In contrast to most preclinical models, humans are gen-
erally diverse in genotypes, diets, other behaviors, and en-
vironmental exposures. Moreover, host genetics and cultural 
milieu profoundly affect flavor perception.132 If the NP will 
be delivered in or as part of a food, liquid, capsule, or tablet, 
acceptability of flavor, texture, and or tablet size are essential. 
For both CT and generally available commercial products, 
consumer burden is another critical factor; this may include 
the number of capsules required, ease of swallowing capsules 
or tablets, cost, and portability. Thus, sensory testing and bur-
den, as well as stability of the NP preparation are critical for 
successful translation of an intervention (Table 3).
Human microbiota are generally much more varied than 
those of lab animal models, reflective of both genetic diver-
sity133 and differences in past exposures.134 Run-in periods 
prior to pharmacokinetic and metabolic assessments can 
increase the relevance of preclinical animal models to long-
term dietary patterns and provide important information for 
comparison with post-intervention metabolite profiles. A 
critical consideration is that, even where preclinical in vivo 
studies are designed to better model (CTs), the models usu-
ally differ from humans in their greater uniformity of back-
ground diet, control of prior exposures to the relevant NP, 
dietary requirements, and metabolic capacities (Table 4). For 
example, taurine is an essential nutrient for cats,135 but syn-
thesized by humans and rodents, while ascorbic acid is es-
sential for humans, but synthesized by most other animals.136
Human genetic differences and variations in gut micro-
biota cannot be considered to be independent, as both direct 
and indirect effects of host genetics on gastrointestinal ecol-
ogy have been reported.133,134,137,138 Both background diet 
and bioactive NPs affect host physiology directly, as well as 
through modulation of the microbiota, and the microbiota in 
turn contribute to modulation of NP processing.139,140 Non-
absorbed polymeric polyphenols may, for example, modulate 
absorption of polyphenol monomers in humans, such that 
history of exposure significantly influences pharmacokinet-
ics.141 Effects on the host may, in turn, modulate microbial 
ecology and metabolism, while changes in microbial pop-
ulations or gene expression may modulate host physiology, 
including ADME, collectively resulting in dynamic host-mi-
crobiota interactions that modulate or even generate the ob-
served responses to ingested interventions.141-146
Gastrointestinal microbiota have been shown in many 
cases to be required for the generation of bioactive metabo-
lites of NPs. For example, gut microbiota can convert grape 
constituents to phenolic acids such as 3-hydroxy benzoic acid 
and dihydrocaffeic acid, which have been reported to inhibit 
β-amyloid and α-synuclein oligomerization, respectively, 
and epigenetically modulate gene expression.3,147 Speakers 
stressed the importance of a strong, though not necessarily 
complete, understanding of the pharmacokinetics and me-
tabolism of a NP intervention for optimizing the design of 
large-scale CT, although opinions differed on whether such 
knowledge was necessary before pursuing early-phase trials.
Presenters highlighted cases where the biological activ-
ities of enantiomeric NPs differ significantly. For example, 
a cancer preventive effect of soy in rodents could be repli-
cated using the R-(+) enantiomer of the isoflavone metabo-
lite equol, but not the S-(-)isomer produced in vivo by the gut 
microbiota.148-152 The microorganisms responsible for this 
conversion are widely present in rodents, but only found in 
only 20%-30% of adult humans, a difference that may con-
tribute to discrepancies between observations in rodents and 
humans. This finding emphasizes the importance of consid-
ering, characterizing, and fully reporting the chirality of NPs 
and their metabolites, as well as of understanding the role of 
the gut microbiota. It was pointed out that translational rele-
vance of in vitro HTS assays might be substantially improved 
through the integrated use of replicable model systems able 
to mimic the generation of translationally relevant metabo-
lites by the target animal or its gut microbiota.
4 |  TRANSLATIONAL 
RELEVANCE OF PRECLINICAL NP 
RESEARCH
4.1 | General considerations
Preclinical in vivo models are widely used in biomedical 
research, and are often considered a prerequisite for CT. 
These models provide critical information on the biological 
response to a product that in silico and in vitro models can-
not currently provide in a reliable fashion, including on bio-
availability, metabolic activation and deactivation, PD, and 
toxicology. In vivo testing also provides a basis for choosing 
dose ranges to be tested in CT.
In selecting any in vivo preclinical model system, inves-
tigators must keep in mind ways in which the differences be-
tween the model and the clinical application of interest are 
likely to affect inference from the study.20 The model selected 
should be appropriate for the experimental question based on 
the organism characteristics considered most critical to the 
target biology. The likelihood of translational relevance of a 
preclinical model to a clinical or other experimental question 
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can be considered in terms of different types of model valid-
ity, including face validity (similar phenotype, lower prob-
ability of successful translation), construct validity (similar 
mechanism and phenotype, better probability of successful 
translation), and clinical validity (demonstrated clinical pre-
dictive success)153-156 (Table 4). For example, short-lived 
invertebrate models may be particularly advantageous to 
understand NP effects on healthspan, as these species con-
serve the target-of-rapamycin, insulin/IGF-1-like signaling, 
and sirtuin pathways, which have been shown to modulate 
healthspan in organisms ranging from yeast through C. ele-
gans and D. melanogaster to mammals.82
Many factors that differ between preclinical in vivo mod-
els and people may influence the biological effects of a NP. 
Background diet and dietary history can influence NP ab-
sorption and metabolism. For example, the absorption and 
PK of flavan-3-ols are altered by exposure history, as well as 
by host factors such as obesity and diabetes.112,141,157,158 This 
demonstrates the critical importance in research on humans 
of considering, assessing, and reporting background diet and 
history, as well as standard biometric parameters. Assessing 
correlations among human genomic, transcriptomic, pro-
teomic, or metabolomic data, and between these and out-
comes following a standardized exposure may elucidate 
mechanisms that underlie differences in the absorption or 
generation of, or exposure to, bioactive constituents or bioac-
tive metabolites,128 and allow prediction of responders versus 
non-responders. These approaches can enhance translation 
between epidemiological, preclinical, and clinical studies.
4.2 | Selection of a mouse model
Mice are frequently the model species of choice for in vivo 
preclinical research, due to their relatively small size and 
short lifespans, and the large number of strains and large 
body of literature available. Nevertheless, mouse and other 
in vivo preclinical models differ from humans in many 
known and unknown details, both intrinsic (eg, genetic, 
immune,159-164 surface area: volume ratio, lifespan165) and 
extrinsic (eg, captivity, diet, history), which, depending on 
the research question, may substantially affect translational 
relevance.166
It is critical to remember that each distinct inbred strain 
may respond differently to an intervention126,167 that the 
same strain supplied by a different vendor (or with different 
gut microbiota) may respond differently,168 and that sex dif-
ferences in response may appear only in specific species or 
strains.169-172
A wide variety of approaches are used to increase the pre-
dictive validity of mouse models. Transgenic mice are com-
monly employed to enhance construct validity; guidelines for 
rigor and transparency in research using mouse mutants have 
been published.173 Transgenic constructs allow experimenta-
tion on specific human pathways and targets of interest. Where 
the genetic mechanism of interest is unknown, for example in 
toxicity testing166,174 or research on neuropathic pain,175 the 
genetic heterogeneity of outbred mice174 may provide im-
portant information that is unavailable from inbred strains 
without otherwise affecting outcome variability.176 Many dif-
ferent approaches to “humanizing” mice have been utilized to 
enhance predictive validity for specific research disciplines 
T A B L E  4  Highlights of good practices for preclinical in vivo 
research on NP
1. Product translational relevance and replicability:
a. Equivalent product formulation. NPs used in preclinical 
studies should use similar or analogous formulation(s) to the 
intended human studies.
b. Biotransformation. Track the actual bioactive compounds, 
which may be generated from precursors in the NP by the host 
or the host’s gut microbiota. Either or both may transform NP 
constituents to active or inactive compounds. These transfor-
mations may differ between models and humans, and among 
humans, and affect replicability of results.
c. Dose-ranging. Doses used in models should be comparable to 
anticipated human dosage. Initial dose ranges may be based 
on traditional use or MPS dose-response studies, derived 
using PBPK modeling, or from preclinical in vivo studies 
using appropriate scaling approaches. A clinical study is still 
required to establish dose-response, assess safety, and deter-
mine PK and PD in the target population.
2. Model translational relevance:
a. Model selection. Consider the translational relevance for the 
specific research question of different species and strains, 
humanized, outbred, wildling, and/or genetically modified 
models. Heterogeneity in the model organisms may contribute 
to the ability to predict responders vs non-responders.
b. Documentation. Document as much as possible. Endogenous 
(eg, age, sex, physiological/health status, genetic), and external 
factors (eg, environment, including background diet, expo-
sure history, enclosure size and enrichment, circadian timing, 
season, duration and timing of exposure relative to outcome 
assessment, handlers and handling methods) may affect out-
comes. Make these records findable, accessible, interoperable, 
reusable (FAIR).100
3. Validated methods for de-risking the NPCT (see also Figure 1): 
Develop and use validated assays to assess achievement of go/no-go 
criteria based on as many components of the mechanistic model as 
possible (see Figure 1), for example, achievement of effective con-
centrations of the bioactive component(s) at in vivo targets, target 
occupancy, and modulation of relevant biological networks.
4. Specimen collection, analysis, and archiving. Collect and ap-
propriately document and store specimens needed for assays 
described in point 3, and as applicable, fecal, or other relevant 
samples to facilitate assessment of any association of the gut 
microbiota with differential responses. In analyses, include 
approaches to control for known artefacts, such as reagent 
contamination that can strongly affect outcomes in low biomass 
microbiome specimens.195
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or questions. Employing the severe combined immune defi-
ciency mouse (SCID) is one such approach, whereby human 
peripheral blood cells, and cells of other human fetal immu-
nological tissues such as bone marrow, thymus, or liver are 
introduced (usually an NOD-SCID-γ mouse).177 Another 
approach involves developing transgenic and chimeric mice 
in which specific human genes are expressed. Various ap-
proaches have also been utilized to generate mice with “hu-
manized” gut microbiota, which have been found to have 
significant clinical predictive validity in developing anti-in-
fective, autoimmune disease, cancer, and transplant therapeu-
tics.178-180 Inbred mice reconstituted with microbiota from 
wild mice have also been reported to have increased trans-
lational value.181,182 In their natural environment mice, like 
humans, are exposed to microbes, including pathogens, and 
thus should be regarded as metaorganisms, with their own 
specific microbiota (including bacteria, fungi, and viruses). 
Returning natural microbiota to standard laboratory mice was 
found to significantly improve the model’s ability to predict 
human immune responses in two preclinical studies.183
4.3 | Model- and context-related 
considerations
Optimization of preclinical research for relevance to future 
NPCTs as well as general human use requires not only careful 
consideration of the choice of models but also of intervention 
dose,184 composition, and delivery (Table 4). As discussed 
above, when research and intervention are founded on a tradi-
tional use, available ethnobotanical and ethnopharmacologi-
cal information may be used for guidance (Table 3). Clinical 
and preclinical interventions should be as similar or, where 
more appropriate, as equivalent as is feasible, bearing in mind 
species differences,185 as well as any age-, sex-, size-, or 
health status-related differences which may affect behavior, 
absorption, metabolism, and/or toxicity. Allometric or mech-
anistic modeling approaches can be used to scale to human 
dosing from preclinical in vivo data, and vice versa.151,184,186
Background diet, as well as other environmental ex-
posures, including medications, alcohol, smoking, and air 
quality may also have important effects on NP bioavailabil-
ity, metabolism, and biological effects in both humans and 
animal models. In the context of NP-diet interactions, it is 
critical to consider species-specific dietary requirements 
and optimal diets (eg, differences in ascorbic acid require-
ments,187 optimal amino acid or lipid compositions),185 as 
well as species differences in biosynthetic abilities188 and 
digestive anatomies.189 When comparing results across stud-
ies, it should be noted that differences in local regulation of 
vertebrate animal research (eg, the European Union prohi-
bition on feeding animal-derived ingredients to herbivores) 
result in substantial differences in commonly used basal diets 
or chows. Researchers must carefully consider, for a given 
research question, whether background diets should be the 
same for different species, or at similar levels of optimization 
for each, or whether both possibilities need to be included 
as controls. As discussed below, physiologically based phar-
macokinetic (PBPK) models may be helpful in making dose 
adjustments for different subpopulations.
Diet and circadian rhythm interact in their effects on health, 
gut microbiota, and metabolism.190,191 These effects are mod-
ulated by sex in organisms ranging from fish and mice through 
humans.192-194 Through their effects on gut microbiota, NPs 
may have important effects on their own metabolism and on 
the generation of active metabolites which, in turn, may sig-
nificantly affect both PK and PD. In addition, changes in the 
gut microbiota may exert separate direct or indirect effects on 
animal biology and health.168 Good practices for characteriza-
tion of the gut microbiota have been discussed elsewhere.195
Preclinical in vivo models are often used in environments 
that are optimized for the investigators and different from the 
species’ natural habitat. This context by itself is likely to af-
fect experimental outcomes and may also modulate the effects 
of an experimental intervention. In either case, the experi-
mental environment is likely to affect translational relevance. 
Investigators need to acknowledge these often unavoidable 
factors and consider them when inferring the translational 
relevance of studies.156 In general, given the range of interre-
lated factors that may modulate the effects of a dietary inter-
vention, it is critical that supporting data include experiments 
rigorously designed to falsify the hypotheses tested, for ex-
ample, to test whether the proposed bioactive constituents or 
metabolite and/or proximate targets are indispensable and 
inducing for the effect studied (Figure 1).35,196
The robustness of a result is optimally assessed by at-
tempting to replicate the study not only in the same model, 
by those originally reporting the result and others, but also 
across models based on a range of species, genotypes, and 
phenotypes. Recording as much information as possible 
about the model and the environmental conditions under 
which it was used may help others to replicate the studies 
or facilitate exploring why a finding failed to replicate, or to 
translate to another model or species.
4.4 | Genetic diversity and gene-NP 
interactions
One critical difference between most preclinical in vivo mod-
els and humans is that the former are usually inbred, except 
as discussed above. Where the bioactive compounds are 
known, and population differences in health response have 
been reported, interrogating those differences may lead to 
the elucidation of underlying gene-environment interactions. 
For example, common genetic variants in two fatty acid 
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desaturase genes (FADS1 and FADS2) appear to modulate 
the response to dietary polyunsaturated fatty acids (PUFA), 
resulting in differences in resulting levels of pro- and anti-
inflammatory lipid mediators and differences in risk for 
inflammation-associated health outcomes such as asthma, 
rheumatoid arthritis, and cancer.197 Tracking the effects of 
prevalence of these variants might shed light on inter-trial dif-
ferences in NPCT outcomes with PUFA interventions.197,198 
Similarly, a variety of factors including biometrics and ge-
netic polymorphisms appear to be responsible for observed 
differences between black and white American women in as-
sociations between serum 25-hydroxy vitamin D levels and 
bone fractures.197-199
4.5 | In silico modeling approaches
Quantitative or computational modeling and simulation are 
beginning to show their utility in optimizing NPCT design. 
Quantitative systems pharmacology (QSP) encompasses 
computational methods including statistics, pharmacomet-
rics, PK and PD modeling, mechanistic or PBPK models, in 
vitro-in vivo extrapolation, and machine learning approaches. 
QSP is often employed in drug development to integrate data, 
optimize experimental dosing regimens, identify sources 
of inter- and intra-individual variability, predict efficacy 
or toxicity, or estimate appropriate doses for different sub-
populations.200-202 PBPK models incorporate physicochemi-
cal data (eg, molecular weight, pKa, lipophilicity), in vitro 
or preclinical data (eg, on metabolism and transport), and 
population-specific data (eg, organ volumes, tissue composi-
tion, blood flow) to model ADME. PBPK can be used to pre-
dict equivalent exposures for humans and other species, for 
both translational and reverse-translational studies (Table 4). 
Sensitivity analyses can allow comparison of the magnitudes 
of the effects of different parameters on the outcomes. These 
models may also provide insight into the interplay between 
metabolizing enzymes and transporters, inter-individual vari-
ability due to intrinsic (eg, pharmacogenomics, age, sex) and 
extrinsic differences (eg, drug, food, or other environmen-
tal exposures). Perhaps most importantly, these computa-
tional models can highlight the most significant gaps in the 
data,203-205 as well as support evidence-based selection of ini-
tial dose ranges for CT.
The application of quantitative pharmacology to complex 
NPs is in its infancy. In addition to the inherent chemical com-
plexity of NPs, understanding of the pharmacology and me-
tabolism of the individual chemical components is mostly very 
limited. Nevertheless, application to NPs of modeling and sim-
ulation approaches that incorporate uncertainty and variability 
can provide estimates of differences among populations, in-
form dose selection and go/no-go decisions, and provide early 
estimates of the probability of rejection of the null hypothesis.
5 |  GOOD PRACTICES FOR 
MOVING TO A NPCT
As outlined above in the section “NP Characteristics 
Critical for Replicability,” speakers emphasized the im-
portance of having rigorous and replicable data on the 
chemical components of the NPs required for the biologi-
cal activities of interest, as well as evidence for the ac-
tivity of interest itself from at least two distinct in vivo 
preclinical models. This information is critical for both 
NPCT planning and for post-trial interpretation of results 
(Figures 1 and 2).
5.1 | NPCT planning
The foundational information should rigorously support 
a clear and specific definition of the question to be ad-
dressed by the NPCT, framed in quantitative terms, and 
matched to the study population, the evaluation period, 
and the primary and secondary outcomes.206,207 When 
strong evidence supports the requirement for specific bio-
active components and specific in vivo targets, this infor-
mation can be used to develop approaches for de-risking 
a project, that is, assessing whether the accumulating data 
are consistent with the hypotheses and support continu-
ation. This information enriches the ability to design a 
NPCT that will allow evidence-based interpretation and 
planning of next steps regardless of the completed out-
come, as shown schematically in Figure 1, by providing 
the ability to:
• define minimal effective concentrations in plasma or at the 
targets;
• develop methods to assess in vivo engagement of putative 
targets, especially methods which may be translationally 
relevant, such as non-invasive methods;
• use those methods to assess the relationship between target 
engagement and outcomes;
• elucidate causal cellular or molecular mechanisms mediat-
ing the generation of the biological or behavioral responses 
of interest (ie, PD biomarkers).
This mechanistic information will be critical for clinical 
dose-ranging and dose optimization studies, as well as for 
detecting potential “drop-ins”: given the broad availabil-
ity of many NPs, placebo group participants sometimes 
present with anomalously high levels of apparent off- 
protocol exposure to the intervention. Off-protocol expo-
sures, whether accidental or intentional, may hamper the 
ability to interpret the results. Knowing which compounds 
are indispensable and inducing for the bioactivities of 
interest also allows investigators to ensure that sufficient 
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time is allowed for washout between inventions in cross-
over designs.26 Equally important, knowledge, for exam-
ple, of minimal effective concentrations and targets, or 
of metabolites indispensable for activity or genotypes 
required to generate those metabolites, can be used to 
generate minimal go/no-go criteria, which help identify 
CTs that are less likely to be informative, and ensure that 
only treatments with strong supporting evidence move for-
ward to larger, confirmatory CT (Figure 2). Elucidation 
of such causal, molecular mechanisms of action may 
also be useful to predict which participants are likely to 
respond well or poorly to a specific intervention. Similarly, 
understanding the molecular mechanisms between an ini-
tial target and the final, assessed outcome should enable 
not only enhanced post-trial assessment of the validity of 
the pre-trial mechanistic hypotheses but also contribute 
to the ability to better predict individual responses to the 
intervention.
5.2 | Safety and dose selection
Safety issues that arise in preclinical testing must be care-
fully considered prior to CT, and safety outcomes must be 
included in all NPCTs.208 Safety in the context of a NPCT 
cannot be inferred from traditional nor contemporary use if 
the product, dose, route, schedule, and context of use differ 
(Table 3). Dosing in larger NPCT should be based on dose-
response data from Phase I/II studies with safety data. Dose-
ranging in Phase I NPCT may use allometric or mechanistic 
models to build from in vivo preclinical studies (Table 4), as 
described above, or, where appropriate, may be based on cur-
rent clinical practice or traditional use.
As described above and summarized schematically in Figure 
2, a variety of rigorous foundational information provides criti-
cal input for translation to later-phase efficacy CT, with much of 
this information requiring input from other types of NIH-defined 
CT. This foundational information includes the following:
F I G U R E  2  Good practices for actionable results in future translation of Natural Products research to Clinical Trials (NP2CT). Translation 
is most informative and cost-effective when CT Phase (I vs II) and design (eg, RCT, adaptive) decisions are built on a solid and rigorous evidence 
base (pyramid and tabletop). The choice to proceed to an NPCT and the determination of the most appropriate trial type (examples on sphere) 
depends on the extent and strength of supporting data available (table legs and segments). If multiple supporting data elements are missing or weak, 
an earlier phase CT may be more informative and cost-effective than a Phase III CT. If a substantial number of CT design choices or parameters 
lack supporting evidence, a more useful next step may be research addressing those gaps via either preclinical research or a mechanistic or early 
phase NPCT 
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• safety of the product to be used in the NPCT, in the popu-
lation to be studied;
• product specifications (for interventions and any controls), 
including chemistry, stability, consumer acceptability (in-
cluding sensory qualities), and packaging;
• bioavailability, PK, PD of the product to be used in the 
population to be studied;
• dose-response properties.
5.3 | Post-trial interpretation of results
In the absence of the foundational information described 
above, and without meeting the resulting go/no-go criteria, 
it will be more challenging to interpret a failure to reject the 
null hypothesis, as lack of effect could be due to many factors 
(Figure 1). These include, but are not limited to an incorrect 
hypothesis regarding the relationship between target engage-
ment and outcome, or less interestingly, failure to achieve 
sufficient levels of bioactive compounds or target engage-
ment. As the following variables could have an important 
influence on the results, obtaining information on these for 
each participant can also be critical to the interpretation of 
NPCT outcomes:
• Background diet—habitual and during the NPCT (the lat-
ter is potentially controllable).
• Age, sex, race/ethnicity, body size and composition, health 
status (especially with respect to outcomes of interest), 
co-medications, smoking, geography.
• Genetic and epigenetic data, including characterization of 
microbiota structure and gene expression, especially as 
they relate to ADME of the NP.134,168,195,209 When known, 
relevant genetic variants exist, for example, in metabolism, 
specimens for genetic analyses should at least be collected 
and saved.
• Sensory characteristics (texture, flavor, odor; pill, capsule, 
etc., number and characteristics) of products to be used in a 
NPCT must be acceptable to trial participants, who should 
not be able to distinguish amongst intervention(s) and con-
trols. Information on participants’ pre-trial beliefs about 
product efficacy, and post-trial conclusions with respect to 
the intervention they received should be collected as this 
may critically inform interpretation (Tables 3 and 5).
5.4 | Addressing expectancy effects
Human responses in NPCTs are also influenced by expecta-
tions, often resulting in either placebo or nocebo effects. These 
effects may vary substantially for different populations and 
interventions (eg, color, size, number of capsules, estimated 
cost).210 Through conscious and subconscious processes, 
people (researchers as well as participants) can be biased when 
assessing and reporting symptoms, functional abilities, and 
other patient-oriented outcomes. Whenever feasible, blinding/
masking and other approaches should be employed to minimize 
such biases, including in preclinical studies (Tables 1 and 5).
Conscious and subconscious mind-body processes can also 
lead to real positive health outcomes, including in apparently 
objective, quantitative outcomes such as blood pressure.211 
Because blinded “placebo” comparison groups are likely to 
achieve real health benefits through these processes, the magni-
tude of benefit estimated by comparing conventionally blinded 
placebo and treatment (intervention) groups is likely to under-
estimate the amount of benefit that would be observed when 
comparing non-blinded treatment to no treatment.212 Therefore, 
when feasible, no treatment and open-label treatment compar-
ison groups should be included in RCT design, so as to arrive 
at best estimates of real-world effect sizes, as well as effect size 
from conventional blinded comparison.
5.5 | Sample and effect size
Sample size calculations must reflect simultaneous con-
sideration of trial phase and design, estimated and targeted 
magnitude of treatment effects, and statistical power.207 
The targeted effect size should be biologically plausible, 
and based on the degree of benefit that patients, consum-
ers, or practitioners would consider sufficiently beneficial 
to be worthwhile, given other considerations such as cost, 
inconvenience, side effects, and potential for serious adverse 
effects213 (Table 5). Effect sizes should not be based on es-
timates from the literature as a whole, which almost always 
leads to biased estimates,214 inasmuch as the published lit-
erature contains a biased selection of all empirical research 
that is performed. Meta-analytic evaluations of the literature 
have consistently found that studies yielding null or mixed 
results are substantially less likely to appear in the published 
scientific record215,216 than those studies with strong statisti-
cal support for the tested hypothesis. This occurs even where 
the amount of collected data renders these “negative” studies 
highly informative. As a result, statistically significant pub-
lished results often provide inflated effect size estimates.217 
Increased use of registered reports, for example, as provided 
by precl inica lrese arch.eu, may begin to address this issue and 
decrease the bias in the scientific literature.
5.6 | Analysis of the literature
Beyond publication bias, two additional factors that chal-
lenge the translational relevance of the published literature 
have been widely agreed upon: analytic flexibility dur-
ing the data analysis218 and low statistical power.40,218,219 
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All of these factors need to be taken into account when 
building on published research. Nevertheless, it should 
be kept in mind that a substantial portion of the scientific 
literature does consist of reliable and replicable findings. 
An important challenge for researchers navigating this in-
trinsically biased body of literature is to determine which 
research is reliable enough to build on, and which research 
is more likely to not be replicable.220 Because it is practi-
cally impossible to determine whether a finding will rep-
licate based on a single study,221 meta-analytic techniques 
have been developed to aggregate evidence across studies. 
However, analytic flexibility and selection for significant 
effects in small studies lead to upwardly biased effect size 
estimates. Novel bias detection techniques can identify dif-
ferent types of biases: P-curve analysis222 can identify lines 
of research that consist of false positives, and under some 
circumstances PET-PEESE meta-regression222,223 can cal-
culate bias-corrected effect size estimates.
5.7 | Clinical trial design
In the design of a later Phase NPCT, it is important to rec-
ognize that estimated treatment effects from pilot studies 
are necessarily imprecise. Pilot studies may under- or over-
estimate the true effect size (but, as noted above, publica-
tion bias generally selects for overestimates). Effect size 
estimates and sample size calculations should, therefore, 
be conservative and based on prospective meta-analyses 
(https ://metho ds.cochr ane.org/pma/what-pma-0) or other 
rigorous meta-analyses, that is, those which include all eli-
gible studies designed and performed, or those which pass 
rigorous bias detection tests, such as the p-curve analysis 
described above, with PET-PEESE meta-regression used 
in estimating effect sizes. Results of pre-registered, rigor-
ously performed, and analyzed pilot studies may also be 
used to estimate effect sizes when convergent, corroborat-
ing, or similar results are obtained in independent research 
from separate groups, using approaches based on differ-
ent assumptions (triangulation or orthogonal approaches), 
such that any artefacts or sources of bias are likely to differ 
for the different approaches.224,225 Adaptive designs (AD) 
(see below) and sequential analyses (https ://metho ds.cochr 
ane.org/pma/what-pma-0) can be used to design informa-
tive studies when uncertainty about the effect size esti-
mate remains. An argument can be made that later Phase 
NPCT intended to test whether an intervention is beneficial 
should be undertaken only where the estimated effect size 
from rigorous methods such as those described above is at 
least as large as the estimated smallest important difference 
or smallest worthwhile effect213 for the intervention and 
outcome to be tested. This would not apply if the hypoth-
esis to be tested is that the intervention has no effect, for 
example, on an adverse outcome.
Where the goal is to determine the maximum potential of 
an intervention, Phase II studies should enroll those subpopula-
tions predicted to have strong responses, a practice called study 
“enrichment.” While enrichment, and the inclusion of multiple 
endpoints are appropriate for Phase II NPCT, it is important to 
recognize that these designs tend to bias the results of Phase 
II studies toward the conclusion that moving forward is worth-
while, although positive findings could be due to chance.
Because NPCT are costly, time-consuming,226 and de-
pendent on voluntary human participation,11 approaches that 
can support making trial design and prioritization decisions 
which optimize acquisition of replicable, actionable results 
(Tables 5 and 6) are in high demand. Multilevel modeling can 
be used in conjunction with existing data to identify parame-
ters most strongly associated with the outcomes of interest.227 
Simulation modeling can also be used to identify trials that 
are unlikely to reject the null hypothesis.228
AD can provide an efficient yet rigorous approach to 
honing the parameters of a NPCT while obtaining pre-
liminary data on clinical effect of the intervention(s). An 
AD uses accumulating information to implement changes 
to the design during the course of the trial.22,229 Changes 
in the trial must be based on pre-specified decision rules. 
Changes made on an ad hoc basis may not preserve the type 
I error rate (false positives), and may lead to bias in param-
eter estimates or other problems with statistical properties. 
The many variations of AD include early-stage AD, which 
may focus on dosing, exposure, heterogeneous responses, 
T A B L E  5  Highlights of major considerations for clinical trial 
design
1. Statistical power. Base sample sizes on the smallest effect size of 
interest, in the context of existing options and consumer burden. 
Use best current meta-analytic approaches to assess bias in the 
literature, and to correct for bias in reported effect sizes.214
2. Transparency and statistical analysis plans. Clearly describe and 
document statistical analysis plans before beginning the trial.
3. Comparison groups and expectancy/placebo. Base controls and 
interventions on the supporting data and the resulting hypoth-
eses. The inclusion of no-treatment, and open-label treatment 
groups, as well as conventional blinded comparison groups, 
in RCTs provides best estimates of real-world effect sizes. 
Development of inert but effectively masked placebos for NPs 
with strong color or odor (eg, with similar or masking odor or 
color) may be challenging. Assessing participant perceptions of 
product efficacy pre-trial, and of intervention allocation post-
trial may provide critical information for interpretation of trial 
results.
4. Optimal clinical trial paradigm. Adaptive design (AD) NPCTs 
may be a more efficient approach to optimizing, and testing the 
efficacy of an intervention, if the evidence base for some CT pa-
rameters is lacking. AD CTs require statistical rigor to avoid bias 
in the interpretation of the results. ADs may be a good choice for 
Phase II trials.
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or biomarker responses. As it is assumed that AD are ex-
ploratory studies, there is less concern about the control of 
type I error. AD methods are more accepted in the learning 
(exploratory) stages of CT. Some key variations of AD in-
clude the following:
• Adaptive enrichment designs, which target therapies to 
participant subgroups most likely to benefit. In such de-
signs, a trial initially enrolls a broad population. The initial 
study period (discovery phase) reveals participant groups 
most likely to benefit from treatment. In the second phase 
of the trial, only those subgroups most likely to benefit 
from treatment are randomized, providing increased power 
to detect an effect.
• Sample size re-estimation designs refer to AD that allow 
for adjustment of sample size based on an interim review 
of the data. Sample size re-estimation based on revised 
estimates of treatment effects has been controversial for 
the reasons cited above. However, internal pilot designs 
that re-estimate only “nuisance” parameters, such as the 
variance of control group event rate, are more generally 
accepted.
• Platform trials are useful for studying multiple targeted 
therapies in the context of a single outcome, with thera-
pies allowed to enter or leave the platform on the basis of 
pre-specified stopping boundaries.22 This approach could 
be used to choose between several different products in a 
NPCT, for example, different preparations of NP material 
from the same source, such as whole dried plant, different 
extracts, and/or material enriched for one or more putative 
bioactives.230 Such studies could be done under a master 
protocol,231 defined as a protocol encompassing multiple 
substudies, which may have different objectives. A mas-
ter protocol supports coordinated efforts to evaluate one or 
more investigational interventions in one or more subpop-
ulations within the overall trial structure.
Adaptive seamless designs combine objectives traditionally ad-
dressed in separate trials into a single CT. First-stage results 
inform the second stage, but final analyses use data from both 
stages. For example, the first stage may establish preferred 
dosage, whereas the second stage can assess the efficacy of 
that dose. To avoid bias in the interpretation of results, such 
designs require clear, comprehensive, and pre-specified criteria 
and raise tricky statistical issues, as data from both stages must 
be combined in a way that preserves key statistical operating 
characteristics.
In general, most AD require slightly larger sample sizes 
than a corresponding, conventional Phase II CT, but provide 
increased opportunity to detect an effect, and can also lead to 
timelier identification of ineffective (or clearly more effica-
cious) interventions, improving efficiency by allowing early 
discontinuation of trials for less effective or ineffective products.
5.8 | Value of information
Whether and how to pursue a NPCT depends on the value 
of the information that the CT can be expected to generate. 
Given the high costs of conducting a CT, it is of critical im-
portance to prioritize the questions to be addressed.11 Value 
of Information (VOI) analysis provides a framework for gen-
erating quantitative estimates of the value of further research 
in a particular area. VOI estimates can serve as a guide for 
prioritizing research resources.232
The basic framework for estimating the VOI is the prod-
uct of several factors: (a) the value of the information to be 
gained for individuals who would be affected by the find-
ings, including both changes in health status and changes 
in costs, (b) the number of affected individuals in the pop-
ulation, (c) the extent to which the information generated 
would be adopted or implemented, and (d) the degree to 
which the value of the knowledge gained will depreciate 
over time as additional knowledge becomes available. This 
estimated quantity is typically summed over the relevant 
time horizon, adjusted by an appropriate discount factor 
reflecting the preference for current over future improve-
ments in health.
Generating estimated values for the elements of the 
VOI calculation can itself be a costly and complex pro-
cess. Depending on the NPs under consideration and the 
effects to be tested, different levels of VOI analysis may 
be undertaken. An initial level of conceptual VOI can as-
sess whether any of the factors in the product are close 
enough to zero that the overall VOI would be very small, 
T A B L E  6  Highlights of major issues to consider in clinical trial 
decision-making
1. Trial focus. Is the proposed trial well-justified? Are the evidence 
for and magnitude of the effect, the size of the relevant popula-
tion, and the need for the knowledge to be generated commensu-
rate with the anticipated cost of a CT?
2. Likelihood of actionable information. What CT paradigm or 
other next step is most likely to provide actionable information?
a. Next step: Is the most informative next step likely to be a 
pilot trial, a larger CT, clinical research other than an efficacy 
study, or research other than a CT?
b. NPCT protocol: Have trial/protocol design decisions been 
sufficiently de-risked? Is there sufficient understanding of 
the path(s) from initial target(s) engagement to outcome, and 
availability of non-invasive assessments of these, to support 
evidence-based decisions regarding the next test of activ-
ity whether or not the null hypothesis is rejected upon trial 
completion?
c. Bioavailability: Are assays of bioavailability at the immediate 
in vivo target available and translationally relevant?
d. Open ends: Can any remaining questions be sufficiently ad-
dressed via use of a rigorous, adaptive trial design?
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indicating that substantial research investments would 
not be justified. Depending on other characteristics of 
the product under investigation, the health outcomes in-
volved, and the specific data collection challenges to be 
addressed, progressively more detailed approaches to VOI 
exist, termed minimal modeling, full modeling, and max-
imal modeling, that provide more thorough estimates of 
the value of the information to be gained from pursuing 
additional research.232,233
The use of VOI analysis to support decisions regarding 
which NPCT to pursue (Table 6) depends significantly on 
the available research foundation. Assessing the VOI to be 
gained to a representative affected individual requires defi-
nition of the outcome(s), and understanding of the effect 
sizes to be achieved. Defining and estimating the size of 
the relevant affected population requires understanding of 
the dietary, environmental, and genetic context of the ef-
fects. Use of VOI in priority setting is still relatively new 
and will benefit from further exploration and input from 
researchers and decision-makers. In particular, VOI should 
be assessed to understand the extent to which it changes 
decision-making relative to conventional approaches, and 
the health impact and monetary value that result from such 
changes.
6 |  CONCLUSIONS
6.1 | The multi-disciplinary approach
Rigorous, evidence-based decision-making with respect 
to the design and prioritization NPCTs ultimately requires 
bringing together myriad research sub-disciplines. These 
disciplines span from ethnobotany through NP chemistry, 
food science, a range of modeling approaches, biomedical 
specialties including CT design and statistics, to value of 
information research. Notably, researchers who special-
ize in one sub-discipline often do not have ready access to 
collaborators from other fields, or are unaware of relevant 
state-of-the-art approaches from these areas. However, the 
likelihood that an NPCT will be optimally informative de-
pends not only on the rigor of the information contributed 
by each sub-discipline but also the rigor with which the 
different threads are brought together, achieving collabora-
tive synergy. Deploying and synergizing the good practices 
discussed by attendees at the September 2018 workshop, 
across the full range of this disciplinary continuum and 
from the earliest phases of developing data that may inform 
a future NPCT, should help focus translational NP research 
on objectives that are most likely to contribute to the design 
of, and increase the knowledge gained from future NPCTs 
(Figure 2).
6.2 | Controversies
Two major areas of controversy at the workshop related to 
translation from traditional health practices. The first of these 
areas of disagreement was the appropriateness of the RCT 
approach for the study of traditional practices, with several 
attendees arguing that RCT methodology is not well suited to 
studying them. Most attendees, however, supported the need 
for NPCTs to assess the safety and efficacy of tradition-based 
approaches in a 21st-century context, with the many asso-
ciated differences, including in the interventions, and in in-
dividuals’ histories, environments, and behaviors. A second 
area of disagreement was the extent to which it is necessary to 
elucidate causal, molecular mechanisms of action, including 
determination of bioactive substituents and their in-animal 
targets, to support the design of an optimally informative 
NPCT. A case was made that, in some contexts, adherence to 
current good manufacturing practices, including rigorous ad-
herence to standardized growing and processing procedures, 
and in conjunction with an appropriate assay of systemic ex-
posure, and, in some cases, bioactivity, is sufficient to ensure 
NP replicability. However, many attendees felt that product 
specifications, PK assessments, eligibility criteria, and out-
come assessments should, to the extent feasible, be based 
on strong mechanism of action evidence, preferably derived 
from conceptually independent (orthogonal or triangulated) 
scientific approaches. Attendees considered such evidence 
to be critical both for optimal trial design and for the abil-
ity to interpret results after trial completion. Information 
on the mechanism of action, including compound(s) indis-
pensable for inducing effects, as well as biological target(s) 
and response(s) indispensable for outcomes, may critically 
inform the design and/or interpretation of an NPCT, from 
product quality control through understanding the bases for 
individual differences in response, and may support the abil-
ity to develop biomarkers of proximate effects, or biomarkers 
useful to distinguish likely responders and non-responders.
6.3 | NCPT good practices
In preclinical research aimed at informing the understanding 
of purported, causal, molecular mechanisms of action, good 
practices include the use of biologically relevant concentra-
tions of biologically relevant compounds and/or their in vivo 
metabolites, in one or more relevant models. Participants 
also emphasized the importance of including appropriate 
controls for common artefacts encountered in in vitro as-
says for the activities of phytochemicals. Further approaches 
that were highlighted as good practices for strengthening the 
foundational data for NPCTs included: (a) high-throughput, 
non-targeted approaches that can generate strong, specific 
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hypotheses regarding molecular mechanisms of action of 
chemically complex NP, (b) pre-registration of experiments 
at the hypothesis-testing stage, rigorous adherence to experi-
mental protocols, randomization, and masking, which collec-
tively minimize the risk that unconscious biases influence the 
results, (c) thoughtful consideration, when selecting model 
systems, of translational relevance and clinical validity for 
a specific research question, and (d) comprehensive and 
transparent reporting, combined with meaningful and FAIR 
data sharing. Participants discussed these issues for models 
ranging from in silico through the burgeoning variety of cell-
based models, from organoids through MPS, through in vivo 
models from invertebrates to transgenic, outbred, wildling, 
and humanized mouse strains.
Good practices for NPCT decision-making based on the 
available foundational data were extensively discussed and 
gave rise to the third major area of controversy at the work-
shop. Some attendees felt that n-of-1 trials234 based on tra-
ditional use and/or current practitioner experience provide 
sufficient evidence for safety and efficacy, and are better 
suited to tests of these approaches than RCTs. Others felt that 
RCTs are critical, but that NPCTs should be undertaken only 
when there is a strong likelihood that the outcome will influ-
ence practice. The foundation for such an assessment would 
come from public health needs and a rigorous, evidence-based 
effect size estimate, that predicts an effect magnitude consid-
ered worthwhile by practitioners and consumers, collectively 
supported by multiple, distinct lines of evidence.225 The evi-
dence base for such assessments is strongest when it includes 
experiments designed to falsify the hypotheses tested, such as 
chemical, genetic, or other knockdown studies.11,35
6.4 | Outlook
While many of the practices discussed at the workshop are 
already employed by numerous NP researchers, few, if any 
reported NPCTs have combined the full breadth of state-of-
the-art approaches when investigating the effect of a NP on 
a specific health outcome. Integrating these practices in the 
development, implementation, and interpretation of NPCTs 
will require research teams to collaborate synergistically 
across disciplines. The anticipated benefit of combining the 
rigorous and trans-disciplinary approaches referenced herein 
increases the likelihood that, in the many instances where the 
outcome of a NPCT does not signal a change in practice, the 
trial will nevertheless have provided actionable new informa-
tion, for example, about NP metabolism or the target biology.
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ENDNOTES
a Per the 2014 NIH guidance, a clinical trial is defined here as a research 
study in which one or more human subjects are prospectively assigned 
to one or more interventions (which may include placebo or other con-
trol) to evaluate the effects of those interventions on health-related 
biomedical or behavioral outcomes (https ://grants.nih.gov/polic y/clini 
cal-trial s/defin ition.htm). 
b Traditional medical systems are defined by the WHO, in the WHO 
Global Report on Traditional and Complementary Medicine 2019 (https 
://apps.who.int/iris/bitst ream/handl e/10665/ 31234 2/97892 41515 436-
eng.pdf?ua=1) as “the sum total of the knowledge, skill and practices 
based on the theories, beliefs and experiences indigenous to different 
cultures, whether explicable or not, used in the maintenance of health as 
well as in the prevention, diagnosis, improvement or treatment of physi-
cal and mental illness.” 
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